Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSPO | P30536 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.49 |
| ▸ | GABRP | O00591 | 2/20 | 0.49 |
| ▸ | GABRD | O14764 | 2/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.49 |
| ▸ | GABRE | P78334 | 2/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14481009 | 0.83 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4818630 | 0.81 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7002012 | 0.81 | NR1H2 (0.48) | LMNAGAATSPOGABRA1GABRG2 | |
| SCHEMBL2759567 | 0.81 | CASP3 (0.53) | LMNAGAATSPOGABRA1GABRG2 | |
| SCHEMBL11120910 | 0.81 | BRPF1 (0.60) | LMNAGAATSPOGABRA1GABRG2 | |
| SCHEMBL14552559 | 0.78 | CLK4 (0.46) | LMNAGAATSPOGABRA1GABRG2 | |
| SCHEMBL22050042 | 0.78 | BRPF1 (0.60) | LMNAGAATSPOGABRA1GABRG2 | |
| SCHEMBL14642438 | 0.77 | BRPF1 (0.41) | LMNAGAATSPOGABRA1GABRG2 | |
| SCHEMBL1364964 | 0.77 | BRPF1 (0.64) | LMNAGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL7556897 | 0.77 | CASP3 (0.57) | LMNAGAAGABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217576-B1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | UNIV MICHIGAN (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2217576-B1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | UNIV MICHIGAN (US) | 2016-05-11 | — | — | EP | disclosed |
| US-8759340-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-24 | — | — | US | disclosed |
| US-8673897-B2 | Benzodiazepinone compounds and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673897-B2 | Benzodiazepinone compounds and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673897-B2 | Benzodiazepinone compounds and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-8461153-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2139331-B1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | UNIV MICHIGAN (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-2139331-B1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | UNIV MICHIGAN (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2008112553-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112553-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-18 | — | — | WO | disclosed |
| US-7375101-B2 | Benzodiazepine derivatives, preparation thereof and use thereof | ASTRAZENECA AB (SE) | 2008-05-20 | — | — | US | disclosed |
| US-7375101-B2 | Benzodiazepine derivatives, preparation thereof and use thereof | ASTRAZENECA AB (SE) | 2008-05-20 | — | — | US | disclosed |
| US-7375101-B2 | Benzodiazepine derivatives, preparation thereof and use thereof | ASTRAZENECA AB (SE) | 2008-05-20 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
| US-20050176699-A1 | Benzodiazepine derivatives, preparation thereof and use thereof | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | US | disclosed |
| EP-1458691-A2 | BENZODIAZEPINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051275-A2 | BENZODIAZEPINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051274-A2 | BENZODIAZEPINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176699-A1 | Benzodiazepine derivatives, preparation thereof and use thereof | GABRA1, GABRA3, GABRA4 | LMNA 1570/4885GAA 4150/4885TSPO 237/4885 |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | LMNA 2002/4885GAA 2723/4885TSPO 554/4885 |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | BAD, GABRA5, GABRB1 | LMNA 3184/4885GAA 3645/4885TSPO 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.